The company claims that its portfolio of eight sharp systems, which includes the Insulin Guard, employs the safety technology.
Visual Connections is transferring this technology to MedPro for a 5% royalty on adjusted net sales after commercialization. MedPro intends to market the Insulin Guard to both current and potential global medical device partners who would in turn brand and sell the Insulin Guard to their worldwide customer base.
Walter Weller, president and COO of MedPro, said: “The Insulin Guard meets a significant need in the home healthcare market for a truly passive safety self-injector that can diminish the risk of accidental needle sticks and related transfer of blood borne pathogens.
“The ‘fully passive’ safety system on the Insulin Guard automatically encloses the contaminated end of the needle immediately after use, thus protecting the patient, the patient’s family, and caregivers. Since the contaminated sharp remains completely covered after use, everyone involved in waste disposal is also protected. We are also investigating the possible use of the Insulin Guard in the hospital setting, which would expand the potential market opportunity.”
